These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25711452)

  • 1. Pharmacogenetic considerations in the treatment of Parkinson's disease.
    Kurzawski M; Białecka M; Droździk M
    Neurodegener Dis Manag; 2015; 5(1):27-35. PubMed ID: 25711452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.
    Arbouw ME; van Vugt JP; Egberts TC; Guchelaar HJ
    Pharmacogenomics; 2007 Feb; 8(2):159-76. PubMed ID: 17286539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease.
    Jiménez-Jiménez FJ; Alonso-Navarro H; García-Martín E; Agúndez JA
    Expert Opin Drug Metab Toxicol; 2016; 12(4):433-48. PubMed ID: 26910127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of drug response in Parkinson's disease.
    Džoljić E; Novaković I; Krajinovic M; Grbatinić I; Kostić V
    Int J Neurosci; 2015; 125(9):635-44. PubMed ID: 25226559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.
    Kalinderi K; Fidani L; Katsarou Z; Bostantjopoulou S
    Int J Clin Pract; 2011 Dec; 65(12):1289-94. PubMed ID: 22093536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease pharmacogenomics: new findings and perspectives.
    Schumacher-Schuh AF; Rieder CR; Hutz MH
    Pharmacogenomics; 2014 Jun; 15(9):1253-71. PubMed ID: 25141900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of pharmacogenomics in the personalization of Parkinson's disease treatment.
    Redenšek S; Dolžan V
    Pharmacogenomics; 2020 Sep; 21(14):1033-1043. PubMed ID: 32893736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease.
    Liu JS; Chen Y; Shi DD; Zhang BR; Pu JL
    Curr Neuropharmacol; 2023; 21(3):536-546. PubMed ID: 36582064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson's disease.
    Ayuso P; Jiménez-Jiménez FJ; Gómez-Tabales J; Alonso-Navarro H; García-Martín E; Agúndez JAG
    Expert Opin Drug Metab Toxicol; 2023; 19(7):447-460. PubMed ID: 37599424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacogenetics in Parkinson's disease treatment].
    Białecka M; Kłodowska-Duda G; Kurzawski M; Droździk M
    Neurol Neurochir Pol; 2008; 42(2):131-8. PubMed ID: 18512170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel insights in pharmacogenetics of drug response in Parkinson's disease.
    Arbouw ME; Guchelaar HJ; Egberts TC
    Pharmacogenomics; 2010 Feb; 11(2):127-9. PubMed ID: 20136351
    [No Abstract]   [Full Text] [Related]  

  • 12. How close are we to individualized medicine for Parkinson's disease?
    Kim HJ; Jeon B
    Expert Rev Neurother; 2016 Jul; 16(7):815-30. PubMed ID: 27105072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions.
    Droździk M; Białecka M; Kurzawski M
    Curr Genomics; 2013 Dec; 14(8):568-77. PubMed ID: 24532988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics of Alzheimer's and Parkinson's diseases.
    Cacabelos R
    Neurosci Lett; 2020 May; 726():133807. PubMed ID: 30236877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson's disease.
    Cacabelos R; Carrera I; Martínez O; Naidoo V; Cacabelos N; Aliev G; Carril JC
    Drug Dev Res; 2021 Aug; 82(5):695-706. PubMed ID: 33458869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.
    Paus S; Grünewald A; Klein C; Knapp M; Zimprich A; Janetzky B; Möller JC; Klockgether T; Wüllner U
    Mov Disord; 2008 Mar; 23(4):599-602. PubMed ID: 18175338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.
    Gilgun-Sherki Y; Djaldetti R; Melamed E; Offen D
    Pharmacogenomics J; 2004; 4(5):291-306. PubMed ID: 15224083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics and the concept of individualized medicine.
    Shastry BS
    Pharmacogenomics J; 2006; 6(1):16-21. PubMed ID: 16302022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.
    Arbitrio M; Di Martino MT; Scionti F; Agapito G; Guzzi PH; Cannataro M; Tassone P; Tagliaferri P
    Oncotarget; 2016 Aug; 7(33):54028-54050. PubMed ID: 27304055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics and human genetic polymorphisms.
    Daly AK
    Biochem J; 2010 Aug; 429(3):435-49. PubMed ID: 20626352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.